Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
出版年份 2014 全文链接
标题
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
作者
关键词
-
出版物
LEUKEMIA
Volume 29, Issue 1, Pages 27-37
出版商
Springer Nature
发表日期
2014-05-05
DOI
10.1038/leu.2014.149
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
- (2013) Sang Min Lim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
- (2013) Giuliana Cassinelli et al. CURRENT MEDICINAL CHEMISTRY
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
- (2013) G S Ducker et al. ONCOGENE
- Targeting oncogenic Ras signaling in hematologic malignancies
- (2012) A. F. Ward et al. BLOOD
- RNAi screening of the kinome with cytarabine in leukemias
- (2012) R. Tibes et al. BLOOD
- Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
- (2012) M. R. Russell et al. CANCER RESEARCH
- Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
- (2012) Amanda K. Arrington et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy
- (2012) Gry Irene Magnussen et al. PLoS One
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Akt, FoxO and regulation of apoptosis
- (2011) Xinbo Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
- (2011) P. C. De Witt Hamer et al. CLINICAL CANCER RESEARCH
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused
- (2011) Ismael Bracho-Valdés et al. IUBMB LIFE
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
- (2011) J. M. Kreahling et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines
- (2011) B. Sarcar et al. MOLECULAR CANCER THERAPEUTICS
- Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
- (2010) K. Yu et al. CANCER RESEARCH
- Unusual Case of Extrapulmonary Metastatic Recurrence in a Patient With Osteosarcoma
- (2010) Vivek S. Radhakrishnan et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
- (2010) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Raptor is Phosphorylated by cdc2 during Mitosis
- (2010) Dana M. Gwinn et al. PLoS One
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started